These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36685585)

  • 1. National experience with adenosine deaminase deficiency related SCID in Polish children.
    Dąbrowska-Leonik N; Piątosa B; Słomińska E; Bohynikova N; Bernat-Sitarz K; Bernatowska E; Wolska-Kuśnierz B; Kałwak K; Kołtan S; Dąbrowska A; Goździk J; Ussowicz M; Pac M
    Front Immunol; 2022; 13():1058623. PubMed ID: 36685585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
    Kohn DB; Gaspar HB
    J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
    Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
    J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic Cell Transplantation for Adenosine Deaminase Severe Combined Immunodeficiency-Improved Outcomes in the Modern Era.
    Ghimenton E; Flinn A; Lum SH; Leahy TR; Nademi Z; Owens S; Williams E; Flood T; Hambleton S; Slatter M; Gennery AR
    J Clin Immunol; 2022 May; 42(4):819-826. PubMed ID: 35288820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
    Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
    J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
    Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
    J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.
    Kuo CY; Garabedian E; Puck J; Cowan MJ; Sullivan KE; Buckley RH; Cunningham-Rundles C; Marsh R; Candotti F; Kohn DB
    J Clin Immunol; 2020 Nov; 40(8):1124-1131. PubMed ID: 32880085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
    Cuvelier GDE; Logan BR; Prockop SE; Buckley RH; Kuo CY; Griffith LM; Liu X; Yip A; Hershfield MS; Ayoub PG; Moore TB; Dorsey MJ; O'Reilly RJ; Kapoor N; Pai SY; Kapadia M; Ebens CL; Forbes Satter LR; Burroughs LM; Petrovic A; Chellapandian D; Heimall J; Shyr DC; Rayes A; Bednarski JJ; Chandra S; Chandrakasan S; Gillio AP; Madden L; Quigg TC; Caywood EH; Dávila Saldaña BJ; DeSantes K; Eissa H; Goldman FD; Rozmus J; Shah AJ; Vander Lugt MT; Thakar MS; Parrott RE; Martinez C; Leiding JW; Torgerson TR; Pulsipher MA; Notarangelo LD; Cowan MJ; Dvorak CC; Haddad E; Puck JM; Kohn DB
    Blood; 2022 Aug; 140(7):685-705. PubMed ID: 35671392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
    Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
    Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.
    Moncada-Vélez M; Vélez-Ortega A; Orrego J; Santisteban I; Jagadeesh J; Olivares M; Olaya N; Hershfield M; Candotti F; Franco J
    Scand J Immunol; 2011 Nov; 74(5):471-81. PubMed ID: 21671975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat ADA deficiency.
    Gaspar HB; Aiuti A; Porta F; Candotti F; Hershfield MS; Notarangelo LD
    Blood; 2009 Oct; 114(17):3524-32. PubMed ID: 19638621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Management Guidelines for Adenosine Deaminase Deficiency.
    Grunebaum E; Booth C; Cuvelier GDE; Loves R; Aiuti A; Kohn DB
    J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1665-1675. PubMed ID: 36736952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine deaminase deficiency: a review.
    Flinn AM; Gennery AR
    Orphanet J Rare Dis; 2018 Apr; 13(1):65. PubMed ID: 29690908
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.